Try Alerts Free   |   Login
Health Care › Pharmaceutical Preparations

GHSI Price Correlated With Financials For Guardion Health Sciences

Free historical financial statements for Guardion Health Sciences Inc.. See how revenue, income, cash flow, and balance sheet financials have changed over 23 quarters since 2017. Compare with GHSI stock chart to see long term trends.

GHSI Stock Compared to Quarterly

GHSI Income Statement

Revenue, Net:2663550
Revenue Per Share:0.0432
Cost of Goods & Services Sold:1575366
Gross Profit:1088184
Selling, General & Admin Expense:2231895
Research & Development Expense:60203
Total Operating Expenses:2827578
Operating Income:-1739394
Net Income:-1696112
Earnings Per Share, Basic:-0.03
Shares Outstanding, Basic Avg:61600823

GHSI Cash Flow

Operating Activities Net Income:
Depreciation, Depletion & Amortization:312217
Change in Accounts Receiveable:-128724
Net Cash from Operations:-1282141
Net Cash from Operations Per Share:-0.0208
Net Cash from Financing Activities:0
Property, Plant & Equipment Purchases:3165
Net Cash from Investing Activities:10003593
Net Change in Cash & Equivalents:8721452

GHSI Balance Sheet

Cash and Cash Equivalents:12946003
Short-Term Investments:null
Accounts Receivable, Net:1873743
Inventories:1952931
Total Current Assets:17811116
Property, Plant & Equipment, Net:53763
Total Assets:28228212
Accounts Payable:1040596
Total Short-Term Liabilities:1733226
Total Liabilities:1733226

Insider Trading

 
Change
Value
Transaction
SEC Form 4
Radoff Bradley Louis   10% Owner
116,721 sh at $7
$825,840
Buy

Major Holders (from 13F filings)

Investment Type
Change
Value (x$1000)
increase or decrease
Renaissance Technologies LLC
1,723,950 sh
-502,292 sh
-23%
$238
-$278
Millennium Management LLC
816,897 sh
451,114 sh
123%
$113
$60
Blackrock Inc.
501,454 sh
 
$69
Susquehanna International Group, Llp
292,640 sh
272,682 sh
1366%
$40
$37
Vanguard Group Inc
288,281 sh
-787,758 sh
-73%
$39
-$116
Barclays Plc
250,000 sh
 
$35
Geode Capital Management, LLC
169,865 sh
 
$23
UBS Group Ag
152,596 sh
74,679 sh
96%
$21
$10
Ergoteles LLC
137,705 sh
137,705 sh
NEW
$19
$19
State Street Corp
134,934 sh
 
$19
Virtu Financial LLC
79,277 sh
-38,717 sh
-33%
$11
-$6
Northern Trust Corp
57,649 sh
32,852 sh
132%
$8
$2
Balyasny Asset Management LLC
44,856 sh
44,856 sh
NEW
$6
$6
Tower Research Capital LLC (Trc)
38,574 sh
-34,628 sh
-47%
$5
-$6
Goldman Sachs Group Inc
25,164 sh
12,611 sh
100%
$3
$1
Morgan Stanley
18,926 sh
156 sh
1%
$3
Citigroup Inc
18,617 sh
 
$3
Raymond James Financial Services Advisors, Inc.
15,000 sh
15,000 sh
NEW
$2
$2
Signaturefd, LLC
996 sh
 
$0
Wells Fargo & Company/Mn
409 sh
259 sh
173%
$0
COMPANY PROFILE
1.
Organization and Business Operations

Business

Guardion
Health Sciences, Inc. (the “Company”) is a clinical nutrition company that offers a portfolio of science-based, clinically
supported products designed to support healthcare professionals and providers and their patients, and consumers.

In
June 2021, the Company acquired Activ Nutritional, LLC (“Activ”), the owner and distributor of the Viactiv® line of supplements
for bone health and other applications (see Note 3). The acquisition significantly changed the operations of the Company, and the integration
of the Viactiv line of products has materially changed the Company’s financial position and operating focus.

Liquidity

The
accompanying consolidated financial statements have been prepared on a going concern basis, which contemplates the realization of assets
and the settlement of liabilities and commitments in the normal course of business. For the three months ended March 31, 2022, the Company
incurred a net loss of $ 2,618,487 and used cash in operating activities of $ 2,226,473. At March 31, 2022, the Company had cash and short-term
investments on hand totaling $ 16,829,612 and working capital of $ 18,741,555.

Notwithstanding
the net loss for the three months ended March 31, 2022, management believes that its current cash and short-term investments as of March
31, 2022 are sufficient to ensure continuation of the Company as a going concern for at least one year from the date of this quarterly
report.

The
amount and timing of future cash requirements will depend, in part, on the Company’s ability to ultimately achieve operating profitability.
The Company expects to continue to incur net losses and negative operating cash flows in the near-term and will continue to incur significant
expenses for the development, commercialization and distribution of its clinical nutrition products and the successful development and
commercialization of any new products or product lines. The Company may also utilize cash to fund additional acquisitions or other strategic
initiatives.

The
Company may seek to raise additional debt and/or equity capital to fund future operations, but there can be no assurances that the Company
will be able to secure such additional financing in the amounts necessary to fully fund its operating requirements on acceptable terms,
or at all. If the Company is unable to access sufficient capital resources on a timely basis, the Company may be forced to reduce
or discontinue its product development programs and/or curtail or cease its operations.

COVID-19

The
Company is subject to risks and uncertainties from the COVID-19 pandemic that could adversely impact the Company’s business. The
Company has implemented health and safety precautions and protocols in response to the pandemic and government guidelines.

The Company’s financial results for the three
months ended March 31, 2022 have been affected by supply chain constraints due, in large part, to the COVID-19 pandemic. These constraints
began in the fourth quarter of 2021 and have continued into 2022 and have impacted the Company’s ability to obtain inventory to
fulfill customer orders for its Viactiv branded products and may continue to impact the Company’s ability to fulfill customer
orders going forward which may have a material adverse effect on the Company’s business and results of operations. The Company
continues to experience some challenges to meet customer demands, largely because of shortages in the Company’s suppliers’
labor, which negatively impacts the availability of many critical components in the Company’s supply chain and distribution. Additionally,
the Company is subject to out-of-stock fees to certain retailers in the event that it is unable to adequately maintain certain inventory
levels of its Viactiv products with such retailers. Although the Company expects these supply chain challenges to continue
through approximately the third quarter of 2022, the Company has begun to see s

Data imported from Guardion Health Sciences Inc. SEC filings. Check original filings before making any investment decision.